NO950244D0 - Dannelse av xenogene antistoffer - Google Patents

Dannelse av xenogene antistoffer

Info

Publication number
NO950244D0
NO950244D0 NO950244A NO950244A NO950244D0 NO 950244 D0 NO950244 D0 NO 950244D0 NO 950244 A NO950244 A NO 950244A NO 950244 A NO950244 A NO 950244A NO 950244 D0 NO950244 D0 NO 950244D0
Authority
NO
Norway
Prior art keywords
loci
human
dna segments
segments
hosts
Prior art date
Application number
NO950244A
Other languages
English (en)
Other versions
NO950244L (no
NO328075B1 (no
Inventor
Raju Kucherlapati
Aya Jakobovits
Sue Klapholz
Daniel G Brenner
Daniel J Capon
Original Assignee
Cell Genesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/031,801 external-priority patent/US6673986B1/en
Application filed by Cell Genesys Inc filed Critical Cell Genesys Inc
Publication of NO950244D0 publication Critical patent/NO950244D0/no
Publication of NO950244L publication Critical patent/NO950244L/no
Publication of NO328075B1 publication Critical patent/NO328075B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO19950244A 1992-07-24 1995-01-23 Fremgangsmate for fremstilling av en gjaercelle, en ikke-human pattedyrembryonisk ES celle, et kimaert ikke-humant pattedyr og et transgent ikke-humant pattedyr samt gjaercelle og isolert ikke-humant pattedyr ES celle. NO328075B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91929792A 1992-07-24 1992-07-24
US08/031,801 US6673986B1 (en) 1990-01-12 1993-03-15 Generation of xenogeneic antibodies
PCT/US1993/006926 WO1994002602A1 (en) 1992-07-24 1993-07-23 Generation of xenogeneic antibodies

Publications (3)

Publication Number Publication Date
NO950244D0 true NO950244D0 (no) 1995-01-23
NO950244L NO950244L (no) 1995-03-23
NO328075B1 NO328075B1 (no) 2009-11-23

Family

ID=26707625

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19950244A NO328075B1 (no) 1992-07-24 1995-01-23 Fremgangsmate for fremstilling av en gjaercelle, en ikke-human pattedyrembryonisk ES celle, et kimaert ikke-humant pattedyr og et transgent ikke-humant pattedyr samt gjaercelle og isolert ikke-humant pattedyr ES celle.

Country Status (11)

Country Link
EP (1) EP0652950B1 (no)
JP (2) JPH07509137A (no)
AT (1) ATE381614T1 (no)
AU (1) AU675661B2 (no)
CA (1) CA2140638C (no)
ES (1) ES2301158T3 (no)
FI (1) FI121339B (no)
NO (1) NO328075B1 (no)
NZ (1) NZ255101A (no)
SG (1) SG48760A1 (no)
WO (1) WO1994002602A1 (no)

Families Citing this family (801)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69133566T2 (de) * 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
KR19980701536A (ko) * 1995-01-20 1998-05-15 케더린 세레다 글라우브 융합된 세포에서 스크린 효과를 개선시키는 방법
US6130364A (en) * 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) * 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6884622B1 (en) 1995-04-21 2005-04-26 Abgenix, Inc Method for preparing a mammalian cell deficient in HPRT
AU2008202860B9 (en) * 1995-04-27 2012-03-29 Amgen Fremont Inc. Human Antibodies Derived From Immunized Xenomice
AU4376400A (en) * 1995-04-27 2000-11-30 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE390933T1 (de) * 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU2466895A (en) * 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
CN1165344C (zh) * 1995-07-21 2004-09-08 内布拉斯卡大学评议会 用于催化水解HIVgp120的组合物及其制备方法和用途
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
EP1854481B1 (en) 1996-04-23 2014-07-16 Chugai Seiyaku Kabushiki Kaisha Cerebral stroke/cerebral edema preventive or remedy containing IL-8 binding inhibitor as active ingredient
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
AU5702298A (en) 1996-12-03 1998-06-29 Abgenix, Inc. Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom
EP2322216A1 (en) 1997-03-21 2011-05-18 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
ATE395933T1 (de) 1997-08-15 2008-06-15 Chugai Pharmaceutical Co Ltd Präventiva oder arzneien enthaltend neutralisierende anti-il6-rezeptor antikörper zur reduktion urinären proteins bei systemischen lupus erythematosus
TWI255853B (en) 1998-08-21 2006-06-01 Kirin Brewery Method for modifying chromosomes
EP1136548A4 (en) 1998-11-04 2002-09-25 Chugai Pharmaceutical Co Ltd NEW SERINE PROTEASES FROM THE TRYPSIN FAMILY
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
PT2112166T (pt) 1998-12-23 2019-01-30 Pfizer Anticorpos monoclonais humanos contra ctla-4
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
EP1961818A3 (en) 1999-04-09 2008-09-10 Chugai Seiyaku Kabushiki Kaisha Novel fetal genes
WO2000075314A1 (fr) 1999-06-02 2000-12-14 Chugai Research Institute For Molecular Medicine, Inc. Proteine receptrice d'hemopoietine
US6833268B1 (en) * 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
CN1370076A (zh) 1999-08-23 2002-09-18 中外制药株式会社 Hm1.24抗原的表达增强剂
KR100942863B1 (ko) 1999-08-24 2010-02-17 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2001018200A1 (fr) 1999-09-06 2001-03-15 Chugai Seiyaku Kabushiki Kaisha Gene de type tsg
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
EP1223217A4 (en) 1999-09-21 2003-06-25 Chugai Pharmaceutical Co Ltd TRANSPORTER GENES OATP-B, C, D AND E
IL148980A0 (en) 1999-10-01 2002-11-10 Chugai Pharmaceutical Co Ltd An antibody to human tissue factor and experimental animals having inserted cells with the gene encoding human tissue factor
ATE409747T1 (de) 2000-01-24 2008-10-15 Haruo Sugiyama Mit wt1 interagierendes protein, wtip
TWI335336B (no) 2000-02-10 2011-01-01 Abbott Gmbh & Co Kg
US6653448B1 (en) 2000-03-29 2003-11-25 Curagen Corporation Wnt-7B-like polypeptides and nucleic acids encoding same
AU2001253339A1 (en) * 2000-04-10 2001-10-23 American Biogenetic Sciences Inc. Human immunoglobulin-producing gnotobiotics
AU2001252618A1 (en) 2000-04-28 2001-11-12 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitors
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
PT2077279E (pt) 2000-06-28 2012-09-14 Amgen Inc Moléculas do receptor de linfopoietina estromal tímica e suas utilizações
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) * 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) * 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1343880B1 (en) * 2000-11-17 2009-05-27 Kyowa Hakko Kirin Co., Ltd. Expression of xenogenous (human) immunoglobulins in cloned, transgenic bovine
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
EP1415005B1 (en) 2000-12-07 2012-11-21 Novartis Vaccines and Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
PE20020801A1 (es) 2001-01-05 2002-09-06 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
JP3986439B2 (ja) 2001-02-07 2007-10-03 中外製薬株式会社 造血器腫瘍の治療剤
CA2441071C (en) 2001-03-14 2010-06-22 Myriad Genetics, Inc. Tsg101-gag interaction and use thereof
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
WO2002081639A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
JP2004536579A (ja) 2001-04-13 2004-12-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 血管内皮増殖因子２
JP4115281B2 (ja) 2001-05-11 2008-07-09 キリンファーマ株式会社 ヒト抗体λ軽鎖遺伝子を含むヒト人工染色体、および子孫伝達可能な該ヒト人工染色体を含む非ヒト動物
EP1463522A4 (en) 2001-05-16 2005-04-13 Einstein Coll Med HUMAN ANTI-PNEUMOCOCCAL ANTIBODIES FROM NON-HUMAN ANIMALS
MXPA03010747A (es) 2001-05-25 2004-03-02 Human Genome Sciences Inc Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
GB0115256D0 (en) * 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
US7981863B2 (en) 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CA2847885C (en) 2001-11-30 2022-03-22 Amgen Fremont Inc. Transgenic animals bearing human ig.lambda. light chain genes
US20050171339A1 (en) 2001-12-28 2005-08-04 Izumi Sugo Method of stabilizing protein
EP1475101B1 (en) 2002-02-14 2010-10-27 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
US7662924B2 (en) 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
US20040023267A1 (en) 2002-03-21 2004-02-05 Morris David W. Novel compositions and methods in cancer
SI1527100T1 (sl) 2002-03-29 2009-12-31 Schering Corp Humana monoklonska protitelesa proti interlevkinu-5 in postopki in sestavki, ki jih obsegajo
US7666610B2 (en) 2002-03-29 2010-02-23 Chugai Seiyaku Kabushiki Kaisha Expressing transporters on viral envelopes
WO2004022597A1 (ja) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
AU2003234736B2 (en) 2002-04-12 2008-09-25 E. R. Squibb & Sons, L.L.C. Methods of treatment using CTLA-4 antibodies
EP2275544A3 (en) 2002-06-06 2011-03-30 Oncotherapy Science, Inc. Genes and polypeptides relating to human colon cancers
SI1513934T1 (sl) 2002-06-06 2011-06-30 Oncotherapy Science Inc Geni in polipeptidi, povezani s humanimi raki kolona
US8518694B2 (en) 2002-06-13 2013-08-27 Novartis Vaccines And Diagnostics, Inc. Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
ZA200500480B (en) 2002-07-15 2006-10-25 Wyeth Corp Methods and compositions for modulating T helper (TH) cell development and function
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
US20060058511A1 (en) 2002-08-27 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Method for stabilizing protein solution preparation
BRPI0314038B8 (pt) 2002-09-06 2021-05-25 Amgen Inc anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica
CA2496400A1 (en) 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
JP5525118B2 (ja) 2002-09-11 2014-06-18 中外製薬株式会社 タンパク質精製方法
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
TW200413539A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Genes and polypeptides relating to prostate cancers
WO2004038018A1 (ja) 2002-10-22 2004-05-06 Eisai Co., Ltd. 分裂停止後のドーパミン産生ニューロン前駆細胞に特異的に発現している遺伝子
AU2003280643A1 (en) 2002-10-30 2004-05-25 Chugai Seiyaku Kabushiki Kaisha Membrane protein originating in mast cells
EP1563084A4 (en) 2002-11-08 2006-03-01 Hematech Llc TRANSGENE UNGULATES WITH REDUCED PRION PROTEIN ACTIVITY AND USES THEREOF
EP2287192B1 (en) 2002-11-15 2015-08-26 Novartis Vaccines and Diagnostics, Inc. Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
EP2363410B1 (en) 2002-11-27 2017-10-11 Minerva Biotechnologies Corporation Isoforms of MUC1
DE60333228D1 (de) 2002-12-02 2010-08-12 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
US7282568B2 (en) 2002-12-16 2007-10-16 Medarex, Inc. Human monoclonal antibodies against interleukin 8 (IL-8)
EP1589106B1 (en) 2002-12-29 2010-12-01 Toudai Tlo, Ltd. Adiponectin receptor and gene coding for the same
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
WO2004074321A2 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic gpcr targets in cancer
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
AU2004224390A1 (en) 2003-03-19 2004-10-07 Abgenix, Inc. Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
EP1627916B1 (en) 2003-05-28 2009-11-25 Takeda Pharmaceutical Company Limited Anti-BAMBI antibodies or RNA for diagnosis and therapy of colon or liver cancer
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
JPWO2005017155A1 (ja) 2003-06-18 2006-10-12 中外製薬株式会社 フコーストランスポーター
AU2004260936B2 (en) 2003-06-27 2010-06-10 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CN1838968A (zh) 2003-08-08 2006-09-27 艾伯吉尼斯公司 针对甲状旁腺激素(pth)之抗体和其用途
EP1654383A1 (en) 2003-08-08 2006-05-10 Licentia, Ltd. Materials and methods for colorectal cancer screening, diagnosis, and therapy
WO2005014818A1 (ja) 2003-08-08 2005-02-17 Perseus Proteomics Inc. 癌高発現遺伝子
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
EP1693448A4 (en) 2003-10-14 2008-03-05 Chugai Pharmaceutical Co Ltd DOUBLE SPECIFICITY ANTIBODY FOR FUNCTIONAL PROTEIN SUBSTITUTION
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US7750123B2 (en) 2003-11-25 2010-07-06 Dana Farber Cancer Institute, Inc. Antibodies against SARS-CoV and methods of use thereof
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
CN1914320A (zh) 2003-12-03 2007-02-14 中外制药株式会社 利用哺乳类β肌动蛋白启动子的表达体系
US7700737B2 (en) 2003-12-05 2010-04-20 Multimmune Gmbh Therapeutic and diagnostic anti-Hsp70 antibodies
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
EP1710255A4 (en) 2003-12-12 2008-09-24 Chugai Pharmaceutical Co Ltd MODIFIED ANTIBODIES RECOGNIZING A TRIMER OR LARGER RECEPTOR
CA2552750C (en) 2004-01-07 2021-11-09 Chiron Corporation M-csf-specific monoclonal antibody and uses thereof
MX370489B (es) 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
US7625549B2 (en) 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
CA2564989C (en) 2004-03-19 2014-05-27 Amgen, Inc. Reducing the risk of human and anti-human antibodies through v gene manipulation
JP4938451B2 (ja) 2004-03-23 2012-05-23 オンコセラピー・サイエンス株式会社 非小細胞肺癌の診断のための方法
EP1786463A4 (en) 2004-03-26 2009-05-20 Human Genome Sciences Inc ANTIBODY AGAINST NOGO RECEPTOR
CN101014715A (zh) 2004-04-22 2007-08-08 麒麟麦酒株式会社 转基因动物及其用途
EP1761784B1 (en) 2004-05-24 2016-10-26 Universität Zu Köln Identification of ergothioneine transporter and therapeutic uses thereof
EP1602926A1 (en) 2004-06-04 2005-12-07 University of Geneva Novel means and methods for the treatment of hearing loss and phantom hearing
AU2005259221B2 (en) 2004-07-01 2011-02-10 Innate Pharma Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
EP2314317A3 (en) 2004-07-09 2011-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
KR20080019733A (ko) 2004-07-16 2008-03-04 화이자 프로덕츠 인코포레이티드 항-아이지에프-1알 항체를 사용하는 비-혈액학적악성종양에 대한 조합 치료
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
JP3996627B2 (ja) 2004-07-22 2007-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｌｒｐ４／Ｃｏｒｉｎドーパミン産生ニューロン前駆細胞マーカー
CA2574881C (en) 2004-08-04 2013-01-08 Amgen Inc. Antibodies to dkk-1
CA2582683A1 (en) 2004-10-01 2006-04-13 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel antibodies directed to the mammalian eag1 ion channel protein
ES2679282T3 (es) 2004-10-22 2018-08-23 Revivicor Inc. Porcinos transgénicos que carecen de cadena ligera de inmunoglobulina endógena
AU2012200570A1 (en) * 2004-10-22 2012-02-23 Revivicor, Inc. Ungulates with genetically modified immune systems
US20080026457A1 (en) 2004-10-22 2008-01-31 Kevin Wells Ungulates with genetically modified immune systems
MX2007005866A (es) 2004-11-17 2007-11-12 Amgen Inc Anticuerpos monoclonales totalmente humanos para il-13.
ATE504602T1 (de) 2004-12-20 2011-04-15 Amgen Fremont Inc Für humane matriptase spezifische bindungsproteine
EP2284194A1 (en) 2004-12-21 2011-02-16 AstraZeneca AB Antibodies directed to angiopoietin-2 and uses thereof
US20090061485A1 (en) 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
WO2006081139A2 (en) 2005-01-26 2006-08-03 Abgenix, Inc. Antibodies against interleukin-1 beta
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
EP2311983A1 (en) 2005-02-10 2011-04-20 Oncotherapy Science, Inc. Method of treating bladder cancer using siRNA
CN101160528A (zh) 2005-02-14 2008-04-09 惠氏公司 Il17-f在诊断和治疗气道炎症中的用途
WO2006088833A2 (en) 2005-02-14 2006-08-24 Wyeth Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor
EP1871807B1 (en) 2005-02-18 2012-11-28 Dana-Farber Cancer Institute, Inc. Antibodies against cxcr4 and methods of use thereof
TWI406870B (zh) 2005-02-21 2013-09-01 Chugai Pharmaceutical Co Ltd A method of making a protein using hamster IGF-1
NZ560844A (en) 2005-03-08 2008-08-29 Pharmacia & Upjohn Co Llc Anti-MAdCAM antibody compositions
WO2007059082A1 (en) 2005-11-10 2007-05-24 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
EP2526957A3 (en) 2005-03-30 2013-02-20 Minerva Biotechnologies Corporation Proliferation of MUC1 expressing cells
ES2720288T3 (es) 2005-03-30 2019-07-19 Minerva Biotechnologies Corp Proliferación de células que expresan MUC1
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
US20090214536A1 (en) 2005-04-07 2009-08-27 Guoying Yu CACNA1E in Cancer Diagnosis, Detection and Treatment
US20090220495A1 (en) 2005-04-07 2009-09-03 Abdallah Fanidi Cancer Related Genes (PRLR)
EP1876236B9 (en) 2005-04-08 2015-02-25 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
WO2006113643A2 (en) 2005-04-20 2006-10-26 Amgen Fremont Inc. High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
EA201100642A1 (ru) 2005-04-25 2011-12-30 Пфайзер Инк. Антитела к миостатину
MX2007013304A (es) 2005-04-26 2007-12-13 Pfizer Anticuerpos de p-caderina.
CA2608474C (en) 2005-05-17 2019-11-12 University Of Connecticut Compositions and methods for immunomodulation in an organism
CA2610987C (en) 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
CN103172738A (zh) 2005-06-30 2013-06-26 Abbvie公司 Il-12/p40结合蛋白
US8067153B2 (en) 2005-07-27 2011-11-29 Oncotheraphy Science, Inc. Genes and polypeptides relating to prostate cancers
EP2311876A3 (en) 2005-07-28 2011-04-27 Novartis AG M-CSF-specific monoclonal antibody and uses thereof
CN101287493A (zh) 2005-08-18 2008-10-15 根马布股份公司 采用cd4结合肽和辐射的疗法
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5415071B2 (ja) 2005-08-19 2014-02-12 ワイス・エルエルシー Ｇｄｆ−８に対するアンタゴニスト抗体ならびにａｌｓおよびその他のｇｄｆ−８関連障害の処置における使用
WO2007024715A2 (en) 2005-08-19 2007-03-01 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
EP2500354A3 (en) 2005-08-19 2012-10-24 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PL2447283T3 (pl) 2005-09-07 2015-12-31 Amgen Fremont Inc Ludzkie przeciwciała monoklonalne przeciwko kinazie podobnej do receptora aktywiny-1 (ALK-1)
RU2396275C2 (ru) 2005-09-29 2010-08-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Молекула адгезии т-клеток и антитело, направленное против молекулы
CA2624562A1 (en) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
JP5014143B2 (ja) 2005-10-14 2012-08-29 学校法人福岡大学 膵島移植における移植膵島障害抑制剤
AR058135A1 (es) 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
US8128934B2 (en) 2005-11-14 2012-03-06 Ribomic, Inc. Method for treatment or prevention of disease associated with functional disorder of regulatory T cell
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
EP1967209B1 (en) 2005-11-25 2012-06-06 Keio University Therapeutic agent for prostate cancer
CN101432302A (zh) 2005-11-30 2009-05-13 艾博特公司 抗－Aβ球聚体抗体，其抗原结合部分，相应的杂交瘤、核酸、载体、宿主细胞，生产所述抗体的方法，包含所述抗体的组合物，所述抗体的应用以及使用所述抗体的方法
CA2631195C (en) 2005-11-30 2016-04-05 Abbott Laboratories Monoclonal antibodies against amyloid beta protein and uses thereof
WO2007065027A2 (en) 2005-12-02 2007-06-07 Dana Farber Cancer Institute Carbonic anhydrase ix (g250) antibodies and methods of use thereof
WO2007067959A2 (en) 2005-12-07 2007-06-14 Medarex, Inc. Ctla-4 antibody dosage escalation regimens
ES2385054T3 (es) 2005-12-13 2012-07-17 Medimmune Limited Proteínas de unión específicas para factores de crecimiento de tipo insulina y usos de las mismas
WO2007074880A1 (ja) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
SG10201400426XA (en) 2006-01-12 2014-07-30 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof
KR101481843B1 (ko) 2006-01-25 2015-01-12 에라스무스 유니버시티 메디컬 센터 로테르담 형질전환 동물 내에서의 중쇄만의 항체의 생성
US8771686B2 (en) 2006-01-27 2014-07-08 Chugai Seiyaku Kabushiki Kaisha Methods for treating a disease involving choroidal neovascularization by administering an IL-6 receptor antibody
US7803561B2 (en) 2006-02-06 2010-09-28 Rhode Island Hospital GPR30 estrogen receptor in breast cancers
EP2010569A4 (en) 2006-03-20 2009-09-09 Xoma Technology Ltd FOR GASTRIN SPECIFIC HUMAN ANTIBODIES, MATERIALS AND METHODS
WO2007123791A2 (en) 2006-03-31 2007-11-01 Dana-Farber Cancer Institute Methods of determining cellular chemosensitivity
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP4218801A3 (en) 2006-03-31 2023-08-23 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
KR20090029184A (ko) 2006-04-07 2009-03-20 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 항체 조성물 및 신생물성 질병의 치료 방법
JP5754875B2 (ja) 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
TW200813231A (en) 2006-04-13 2008-03-16 Novartis Vaccines & Diagnostic Methods of treating, diagnosing or detecting cancer
US20100080794A1 (en) 2006-04-14 2010-04-01 Takashi Tsuji Mutant polypeptide having effector function
US8293245B2 (en) 2006-04-20 2012-10-23 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on Shiga toxin type 1 protein
WO2007129457A1 (ja) 2006-04-25 2007-11-15 The University Of Tokyo アルツハイマー病および癌の治療薬
CN103272232B (zh) 2006-06-08 2018-07-24 中外制药株式会社 炎性疾病的预防或治疗药
US20100040600A1 (en) 2006-06-14 2010-02-18 Chugai Seiyaku Kabushiki Kaisha Agents for Promoting the Growth of Hematopoietic Stem Cells
WO2007150069A2 (en) 2006-06-23 2007-12-27 Myriad Genetics, Inc. Dpyd gene variants and use thereof
JPWO2008007755A1 (ja) 2006-07-13 2009-12-10 中外製薬株式会社 細胞死誘導剤
EP2574625B1 (en) 2006-07-21 2015-02-25 HuBit genomix, Inc. Remedy for renal disease
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
MX2009001293A (es) 2006-08-03 2009-02-11 Astrazeneca Ab Anticuerpos dirigidos a (v(6 y usos de los mismos.
EP2054444B1 (en) 2006-08-04 2016-11-02 MedImmune Limited Antibodies to erbb2
JP5406027B2 (ja) 2006-08-04 2014-02-05 ノバルティス アーゲー ＥｐｈＢ３特異的抗体およびその使用
EP3111955B1 (en) 2006-08-14 2019-01-23 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-desmoglein-3 antibody
KR101433544B1 (ko) 2006-08-18 2014-08-27 노바르티스 아게 Ｐｒｌｒ 특이적 항체 및 그 용도
US20090053210A1 (en) 2006-09-01 2009-02-26 Roland Buelow Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
CN102719444B (zh) 2006-09-01 2016-12-14 人类多细胞株治疗学公司 人或人源化免疫球蛋白在非人转基因动物中增强的表达
KR101544108B1 (ko) 2006-09-08 2015-08-13 애브비 바하마스 리미티드 인터루킨-13 결합 단백질
EP2083017A4 (en) 2006-09-14 2011-01-12 Med & Biological Lab Co Ltd ANTIBODIES HAVING INCREASED ADCC ACTIVITY AND METHOD FOR PRODUCING THE SAME
MX2009003393A (es) 2006-10-02 2009-05-11 Regeneron Pharma Anticuerpos humanos de alta afinidad para el receptor de il-4 humano.
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CA2664567C (en) 2006-10-04 2016-04-26 Dana-Farber Cancer Institute, Inc. Tumor immunity
CA2665528C (en) 2006-10-12 2018-01-23 The University Of Tokyo Diagnosis and treatment of cancer using anti-ereg antibody
EP2093237B1 (en) 2006-10-20 2015-12-30 Chugai Seiyaku Kabushiki Kaisha Anti-cancer agent comprising anti-hb-egf antibody as active ingredient
JP5378795B2 (ja) 2006-10-20 2013-12-25 中外製薬株式会社 抗ｈｂ−ｅｇｆ抗体を有効成分として含む医薬組成物
JP5570218B2 (ja) 2006-11-03 2014-08-13 ユースリー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｆｇｆｒ４抗体
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
AU2007329307B2 (en) 2006-12-07 2012-08-02 Novartis Ag Antagonist antibodies against EphB3
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
CA2672581A1 (en) 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
EP2094306A2 (en) 2006-12-20 2009-09-02 XOMA Technology Ltd. Treatment of il-1-beta related diseases
US20100111851A1 (en) 2007-01-05 2010-05-06 The University Of Tokyo Diagnosis and treatment of cancer by using anti-prg-3 antibody
PT2099826E (pt) 2007-01-05 2014-01-09 Univ Zuerich Anticorpo anti-beta-amilóide e suas utilizações
US7776331B1 (en) 2007-01-16 2010-08-17 Abbott Laboratories Methods of treating plaque psoriasis
TWI438208B (zh) 2007-01-23 2014-05-21 Chugai Pharmaceutical Co Ltd 抑制慢性排斥反應之藥劑
EP2119777A4 (en) 2007-02-09 2011-05-25 Eisai R&D Man Co Ltd GABA NEURONS TEMPLATE MARKER 65B13
US20100216977A1 (en) 2007-02-15 2010-08-26 Kyushu University, National University Corporation Therapeutic agent for interstitial pulmonary disease comprising anti-hmgb-1 antibody
CN101951953A (zh) 2007-02-27 2011-01-19 株式会社未来创药研究所 含抗grp78抗体作为有效成分的药物组合物
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
CL2008000719A1 (es) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
CA2680914C (en) 2007-03-13 2019-06-18 University Of Zurich Monoclonal human tumor-specific antibody
EP2125898B1 (en) 2007-03-14 2013-05-15 Novartis AG Apcdd1 inhibitors for treating, diagnosing or detecting cancer
BRPI0809042B1 (pt) 2007-03-22 2021-08-31 Biogen Ma Inc. Proteína de ligação a cd154 isolada, seu uso, e composição
CA2682927A1 (en) 2007-04-02 2008-10-16 Amgen Fremont Inc. Anti-ige antibodies
JP5117765B2 (ja) 2007-05-28 2013-01-16 国立大学法人 東京大学 抗ｒｏｂｏ１抗体を含むｐｅｔ用腫瘍診断剤
LT2602323T (lt) 2007-06-01 2018-04-10 Open Monoclonal Technology, Inc. Kompozicijos ir būdai endogeninių imunoglobulinų genams slopinti ir transgeniniams žmogaus idiotipo antikūnams gaminti
WO2009001840A1 (ja) 2007-06-25 2008-12-31 Forerunner Pharma Research Co., Ltd. ADCC活性又はCDC活性を有する抗Prominin-1抗体
JP5354680B2 (ja) 2007-07-10 2013-11-27 塩野義製薬株式会社 Ｍｍｐ１３に対する中和活性を有するモノクローナル抗体
WO2009014263A1 (ja) 2007-07-26 2009-01-29 Osaka University インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
MX2010001307A (es) 2007-08-02 2010-07-30 Novimmune Sa Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos.
SG183698A1 (en) 2007-08-20 2012-09-27 Oncotherapy Science Inc Cdca1 peptide and pharmaceutical agent comprising the same
JP5555952B2 (ja) 2007-08-20 2014-07-23 オンコセラピー・サイエンス株式会社 Ｆｏｘｍ１ペプチドおよびこれを含む薬剤
ES2632123T3 (es) 2007-08-20 2017-09-11 Oncotherapy Science, Inc. Péptido CDH3 y agente medicinal que comprende el mismo
SI2188313T1 (en) 2007-08-21 2018-04-30 Amgen, Inc. HUMAN C-FMS ANTIGEN TRANSFER PROTEIN
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
EP2615114B1 (en) 2007-08-23 2022-04-06 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
EP2527369A3 (en) 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
EP2497783A3 (en) 2007-09-26 2013-04-17 U3 Pharma GmbH Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
SI2202245T1 (sl) 2007-09-26 2016-10-28 Chugai Seiyaku Kabushiki Kaisha Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
AR066172A1 (es) 2007-09-28 2009-07-29 Chugai Pharmaceutical Co Ltd Metodo para la preparacion de un anticuerpo antiglipicano 3 con modulada cinetica plasmatica mediante variacion de la semivida plasmatica.
CN101815532B (zh) 2007-10-02 2012-08-15 中外制药株式会社 以白细胞介素6受体抑制剂为有效成分的移植物抗宿主病治疗剂
KR101558009B1 (ko) 2007-10-15 2015-10-19 추가이 세이야쿠 가부시키가이샤 항체의 제조 방법
KR20100115340A (ko) 2007-10-19 2010-10-27 이무나스 파마 가부시키가이샤 Ａβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용
EP2230300A4 (en) 2007-10-24 2012-08-08 Otsuka Chemical Holdings Co Ltd POLYPEPTIDE WITH IMPROVED EFFECTOR FUNCTION
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
DK2220121T3 (en) 2007-11-12 2015-12-07 U3 Pharma Gmbh AXL antibodies
WO2009063970A1 (ja) 2007-11-14 2009-05-22 Forerunner Pharma Research Co., Ltd. 抗gpr49抗体を用いる癌の診断および治療
SG188134A1 (en) 2007-11-15 2013-03-28 Chugai Pharmaceutical Co Ltd Monoclonal antibody capable of binding to anexelekto, and use thereof
CA2705923A1 (en) 2007-11-16 2009-05-22 Nuvelo, Inc. Antibodies to lrp6
KR101643005B1 (ko) 2007-12-05 2016-07-28 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
EP2241332A4 (en) 2007-12-05 2011-01-26 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT AGAINST PRITURE
EP3524619A1 (en) 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
US20110262425A1 (en) 2007-12-12 2011-10-27 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
CN101945891A (zh) 2007-12-20 2011-01-12 爱克索马技术有限公司 治疗痛风的方法
EP2261254A3 (en) 2007-12-21 2011-04-13 Amgen, Inc Anti-amyloid antibodies and uses thereof
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2009086514A1 (en) 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
SG187457A1 (en) 2008-01-11 2013-02-28 Univ Tokyo Anti-cldn6 antibody
WO2009094551A1 (en) 2008-01-25 2009-07-30 Amgen Inc. Ferroportin antibodies and methods of use
PL2246427T3 (pl) 2008-02-08 2017-06-30 Immunas Pharma, Inc. Przeciwciała zdolne do wiązania się swoiście do oligomerów amyloidu beta i ich stosowanie
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
RU2497545C2 (ru) 2008-03-18 2013-11-10 Эбботт Лэборетриз Способ лечения псориаза (варианты)
CL2009000647A1 (es) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
PL2275443T3 (pl) 2008-04-11 2016-05-31 Chugai Pharmaceutical Co Ltd Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny
KR20110014607A (ko) 2008-04-29 2011-02-11 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
JP2011519279A (ja) 2008-05-01 2011-07-07 アムジエン・インコーポレーテツド 抗ヘプシジン抗体及び使用の方法
WO2009136382A2 (en) 2008-05-09 2009-11-12 Abbott Gmbh & Co. Kg Antibodies to receptor of advanced glycation end products (rage) and uses thereof
WO2009147781A1 (ja) 2008-06-02 2009-12-10 国立大学法人東京大学 抗がん剤
MX2010013239A (es) 2008-06-03 2011-02-24 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
UY31861A (es) 2008-06-03 2010-01-05 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
CN104906581A (zh) 2008-06-05 2015-09-16 国立研究开发法人国立癌症研究中心 神经浸润抑制剂
WO2009154025A1 (ja) 2008-06-20 2009-12-23 国立大学法人岡山大学 酸化LDL/β2GPI複合体に対する抗体及びその用途
RU2559525C2 (ru) 2008-07-08 2015-08-10 Эббви Инк Белки, связывающие простагландин е2, и их применение
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
SG10201701323TA (en) 2008-08-18 2017-04-27 Amgen Fremont Inc Antibodies to ccr2
CA2736799A1 (en) 2008-08-25 2010-03-11 Burnham Institute For Medical Research Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
CN102264763B (zh) 2008-09-19 2016-04-27 米迪缪尼有限公司 定向于dll4的抗体及其用途
PL2346994T3 (pl) 2008-09-30 2022-04-19 Ablexis, Llc Myszy knock-in do wytwarzania chimerycznych przeciwciał
KR20140101876A (ko) 2008-10-09 2014-08-20 미네르바 바이오테크놀로지 코포레이션 세포내에서 다능성을 유도하기 위한 방법
PE20120021A1 (es) 2008-10-10 2012-02-10 Amgen Inc Mutantes fgf21
ES2548377T3 (es) 2008-10-27 2015-10-16 Revivicor, Inc. Ungulados inmunodeprimidos
DK2894165T3 (da) 2008-11-10 2023-03-20 Alexion Pharma Inc Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser
AU2009328505B2 (en) 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
JP5756292B2 (ja) 2008-12-22 2015-07-29 中外製薬株式会社 抗ｈｓ６ｓｔ２抗体及びその用途
WO2010073972A1 (ja) 2008-12-22 2010-07-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｎｅｐｈ３を用いた膵臓前駆細胞の取得方法
JP2012513194A (ja) 2008-12-23 2012-06-14 アストラゼネカ アクチボラグ α５β１に向けられた標的結合剤およびその使用
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
EP2385114A4 (en) 2008-12-25 2012-08-08 Univ Tokyo CANCER TREATMENT DIAGNOSIS WITH ANTI-TM4SF20 ANTIBODY
KR20110099762A (ko) 2008-12-26 2011-09-08 고쿠리츠다이가쿠호우진 도쿄다이가쿠 항ｌｇｒ７항체를 사용하는 암의 진단 및 치료
US8309530B2 (en) 2009-02-04 2012-11-13 Washington State University Compositions and methods for modulating ghrelin-mediated conditions
NZ611324A (en) 2009-03-05 2015-02-27 Abbvie Inc Il-17 binding proteins
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
CA2889453C (en) 2009-03-20 2018-11-06 Amgen Inc. Carrier immunoglobulins and uses thereof
US9079957B2 (en) 2009-04-16 2015-07-14 The University Of Tokyo Diagnosis and treatment of cancer using anti-TMPRSS11E antibody
DK2419447T3 (en) 2009-04-17 2017-09-25 Immunas Pharma Inc ANTIBODIES THAT SPECIFICALLY BIND TO A BETA OLIGOMER AND USE THEREOF
AU2010242338B2 (en) 2009-05-01 2013-12-19 Perseus Proteomics Inc. Anti-cadherin antibody
MX2011011815A (es) 2009-05-05 2012-01-27 Amgen Inc Mutantes fgf21 y usos de los mismos.
CN107188950B (zh) 2009-05-05 2021-09-28 安姆根有限公司 Fgf21突变体及其用途
MX2011011729A (es) 2009-05-05 2012-04-10 Novimmune Sa Anticuerpo anti il-17f y metodos de uso de los mismos.
EP2436397B1 (en) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
HUE055817T2 (hu) 2009-07-08 2021-12-28 Kymab Ltd Állatmodellek és terápiás molekulák
EP2287336A1 (fr) 2009-07-31 2011-02-23 Exhonit Therapeutics SA Procédés et méthodes de diagnostic de la maladie d'Alzheimer
WO2011013786A1 (ja) 2009-07-31 2011-02-03 Maeda Shin 癌の転移抑制剤
EP2462451B1 (en) 2009-08-05 2016-02-17 Nexigen GmbH Human hcv-interacting proteins and methods of use
ES2614949T3 (es) 2009-08-06 2017-06-02 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a oligómeros beta A y uso de los mismos
DK2462161T3 (en) 2009-08-06 2017-06-06 Immunas Pharma Inc Antibodies specifically binding to A-beta oligomers and their use
CA2771436A1 (en) 2009-08-17 2011-02-24 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
WO2011024114A1 (en) 2009-08-25 2011-03-03 Ecole Polytechnique Federale De Lausanne (Epfl) Targeting extracellular matrix molecules for the treatment of cancer
US8313747B2 (en) * 2009-08-28 2012-11-20 Vlst Corporation Antikine antibodies that bind to multiple CC chemokines
PE20121647A1 (es) 2009-08-29 2012-12-31 Abbvie Inc Proteinas terapeuticas de union a dll4
UY32870A (es) 2009-09-01 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
MX2012003138A (es) 2009-09-14 2012-07-04 Abbott Lab Y Abbott Gmbh & Co Kg Metodos para tratar la psoriasis.
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
AU2010298036B2 (en) 2009-09-25 2015-05-21 Xoma Technology Ltd. Screening methods
EP2305285A1 (en) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Means and methods for treating ischemic conditions
RU2012119756A (ru) 2009-10-15 2013-11-20 Эбботт Лэборетриз Иммуноглобулины с двумя вариабельными доменами и их применение
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TW201121568A (en) 2009-10-31 2011-07-01 Abbott Lab Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
EP2496604B1 (en) 2009-11-06 2017-08-23 IDEXX Laboratories, Inc. Canine anti-cd20 antibodies
GB0919751D0 (en) 2009-11-11 2009-12-30 King S College Hospital Nhs Fo Conjugate molecule
JP5931736B2 (ja) 2009-11-13 2016-06-08 ウー３・フアルマ・ゲー・エム・ベー・ハーＵ３ Ｐｈａｒｍａ Ｈｅｒ−３関連疾患を治療または予防するための物質および方法
AU2010321832B2 (en) 2009-11-20 2014-08-14 Amgen Inc. Anti-Orai1 antigen binding proteins and uses thereof
CA2992770A1 (en) 2009-11-24 2011-06-03 Medimmune Limited Targeted binding agents against b7-h1
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
WO2011070045A1 (en) 2009-12-08 2011-06-16 Abbott Gmbh & Co. Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
CA2786692A1 (en) 2010-01-11 2011-07-14 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
JP5104996B2 (ja) 2010-01-29 2012-12-19 東レ株式会社 ポリ乳酸系樹脂シート
JP5918540B2 (ja) 2010-01-29 2016-05-18 中外製薬株式会社 抗ｄｌｌ３抗体
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
NZ719253A (en) 2010-02-08 2022-08-26 Regeneron Pharma Common light chain mouse
CA2789310C (en) 2010-02-10 2018-01-09 Fujifilm Ri Pharma Co., Ltd. Radioactive metal-labeled anti-cadherin antibody
WO2011103426A2 (en) 2010-02-19 2011-08-25 The Board Of Regents Of The University Of Oklahoma Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof
US20120321557A1 (en) 2010-02-26 2012-12-20 Forerunner Pharma Research Co., Ltd. Anti-icam3 antibody and use thereof
WO2011109298A2 (en) 2010-03-02 2011-09-09 Abbott Laboratories Therapeutic dll4 binding proteins
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
CA3006800C (en) 2010-03-31 2022-10-04 Ablexis, Llc Genetic engineering of non-human animals for the production of chimeric antibodies
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
SI2563813T1 (sl) 2010-04-30 2015-12-31 Alexion Pharmaceuticals, Inc. Protitelesa anti-C5A in postopki uporabe protiteles
UY33386A (es) 2010-05-14 2011-12-30 Abbott Laboratoires Proteínas de unión a il-1
JP6051049B2 (ja) 2010-05-28 2016-12-21 中外製薬株式会社 抗腫瘍ｔ細胞応答増強剤
JP5904552B2 (ja) 2010-05-28 2016-04-13 国立研究開発法人国立がん研究センター 膵癌治療剤
CA2800531C (en) 2010-06-02 2021-05-25 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
CA2803588A1 (en) 2010-06-22 2011-12-29 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the c3d fragment of complement component 3
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TW201206473A (en) 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US20120156130A1 (en) 2010-08-06 2012-06-21 Thore Hettmann Use of her3 binding agents in prostate treatment
MX2013001632A (es) 2010-08-10 2013-06-05 Amgen Inc Ensayo de enlace objetivo in vitro de funcion doble para la deteccion de anticuerpos neutralizantes contra anticuerpos objetivo.
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
SI3333188T1 (sl) 2010-08-19 2022-04-29 Zoetis Belgium S.A. Protitelesa proti NGF in njihova uporaba
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
EP2609431B1 (en) 2010-08-27 2017-05-10 University of Zurich Method for target and drug validation in inflammatory and/or cardiovascular diseases
WO2012028697A1 (en) 2010-09-01 2012-03-08 Eth Zürich, Institute Of Molecular Biology And Biophysics Affinity purification system based on donor strand complementation
MY188828A (en) 2010-09-17 2022-01-06 Takeda Pharmaceuticals Co Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph
CA2814780C (en) 2010-09-22 2017-05-16 Amgen Inc. Carrier immunoglobulins and uses thereof
EP2627672B1 (en) 2010-10-11 2018-08-01 Biogen Idec International Neuroscience GmbH Human anti-tau antibodies
EP2632481A1 (en) 2010-10-25 2013-09-04 Regents Of The University Of Minnesota Therapeutic composition for treatment of glioblastoma
MX354481B (es) 2010-10-27 2018-03-07 Amgen Inc Anticuerpos dkk1 y métodos de uso.
EP3404043B1 (en) 2010-10-29 2022-10-26 Perseus Proteomics Inc. Anti-cdh3 antibody having high internalization capacity
KR101398363B1 (ko) 2010-11-17 2014-05-22 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
PL2647707T3 (pl) 2010-11-30 2019-02-28 Chugai Seiyaku Kabushiki Kaisha Środek terapeutyczny wywołujący cytotoksyczność
MX365235B (es) 2010-11-30 2019-05-28 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
CN103380145B (zh) 2010-12-17 2016-10-12 生物控股有限公司 人类抗-sod1抗体
CN103874503A (zh) 2010-12-21 2014-06-18 瑟莱克斯制药公司 抗p-选择素抗体及其使用和鉴定方法
JP6009455B2 (ja) 2010-12-21 2016-10-19 アッヴィ・インコーポレイテッド Ｉｌ−１アルファおよびベータ二重特異的二重可変ドメイン免疫グロブリンおよびその使用
WO2012088094A2 (en) 2010-12-21 2012-06-28 Abbott Laboratories Il-1 binding proteins
WO2012092376A2 (en) 2010-12-31 2012-07-05 Short Jay M Comprehensive monoclonal antibody generation
US20120185956A1 (en) 2011-01-18 2012-07-19 Gingras Jacinthe Global nav1.7 knockout mice and uses
WO2012102679A1 (en) 2011-01-24 2012-08-02 National University Of Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
US9447187B2 (en) 2011-02-03 2016-09-20 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
WO2012104824A1 (en) 2011-02-04 2012-08-09 Ecole polytechnique fédérale de Lausanne (EPFL) Therapeutic antibodies targeting app-c99
US20140044644A1 (en) 2011-02-21 2014-02-13 University Of Zurich Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
EP2679681B2 (en) 2011-02-25 2023-11-15 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific FC antibody
CN103649118A (zh) 2011-03-01 2014-03-19 安进公司 双特异性结合剂
EP4086338A1 (en) 2011-03-17 2022-11-09 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
EP2500073A1 (en) 2011-03-17 2012-09-19 ChromaCon AG Method for identification and purification of multi-specific polypeptides
WO2012129520A1 (en) 2011-03-24 2012-09-27 Texas Tech University System Tcr mimic antibodies as vascular targeting tools
DK2698431T3 (da) 2011-03-30 2020-11-30 Chugai Pharmaceutical Co Ltd Opretholdelse af antigen-bindende molekyler i blodplasma og fremgangsmåde til modifikation af immunogenicitet
KR20140027211A (ko) 2011-04-04 2014-03-06 유니버시티 오브 아이오와 리써치 파운데이션 백신 면역원성의 개선 방법
CA2831957A1 (en) 2011-04-07 2012-10-11 Amgen Inc. Novel egfr binding proteins
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
US20140193420A1 (en) 2011-04-18 2014-07-10 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-itm2a antibody
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
EP2710037B1 (en) 2011-05-19 2019-07-31 The Regents of The University of Michigan Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
EP2530088A1 (en) 2011-05-30 2012-12-05 Klinikum rechts der Isar der Technischen Universität München Means and methods for diagnosing and treating multiple sclerosis
MX351600B (es) 2011-06-03 2017-10-20 Xoma Technology Ltd Anticuerpo especificos para tgf-beta.
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
US20140227265A1 (en) 2011-06-17 2014-08-14 Amgen Inc. Method of treating or ameliorating metabolic disorders using clec-2
TR201815563T4 (tr) 2011-06-23 2018-11-21 Biogen Int Neuroscience Gmbh Anti-alfa sinüklein bağlayıcı moleküller.
BR112013032630B1 (pt) 2011-06-30 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Polipeptídeo heterodimerizado compreendendo região fc de igg
DE202011103324U1 (de) 2011-07-12 2012-01-02 Nekonal S.A.R.L. Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
JP2014520847A (ja) 2011-07-13 2014-08-25 アッヴィ・インコーポレイテッド 抗ｉｌ−１３抗体を使用して喘息を治療するための方法および組成物
JP6176849B2 (ja) 2011-07-19 2017-08-09 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
WO2013017656A1 (en) 2011-08-02 2013-02-07 Medizinische Universität Wien Antagonists of ribonucleases for treating obesity
EP2739652B1 (en) 2011-08-04 2017-04-05 Medizinische Universität Innsbruck Cahgt1p inhibitors for use in the treatment of candidiasis
SG2014007686A (en) 2011-08-05 2014-03-28 Regeneron Pharma Humanized universal light chain mice
EP2749572A4 (en) 2011-08-23 2015-04-01 Chugai Pharmaceutical Co Ltd NEW ANTI-DDR1 ANTIBODY WITH ANTITUMORACTIVITY
WO2013035824A1 (ja) 2011-09-07 2013-03-14 ファーマロジカルズ・リサーチ プライベート リミテッド 癌幹細胞の分離
CN103945689B (zh) 2011-09-19 2016-10-19 科马布有限公司 免疫球蛋白基因多样性的操纵及多抗体治疗剂
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
KR102239138B1 (ko) 2011-09-30 2021-04-12 추가이 세이야쿠 가부시키가이샤 표적 항원에 대한 면역응답을 유도하는 항원 결합 분자
WO2013046722A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 イオン濃度依存性結合分子ライブラリ
SI2760471T1 (sl) 2011-09-30 2017-04-26 Dana-Farber Cancer Institute, Inc. Terapevtski peptidi
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
KR102143331B1 (ko) 2011-09-30 2020-08-11 추가이 세이야쿠 가부시키가이샤 항원의 소실을 촉진시키는 항원 결합 분자
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP2764118A1 (en) 2011-10-05 2014-08-13 University of Bremen Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases
JP6271251B2 (ja) 2011-10-05 2018-01-31 中外製薬株式会社 糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子
AU2012326137B2 (en) 2011-10-17 2018-11-29 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
BR112014009536A2 (pt) 2011-10-21 2017-04-18 Augurex Life Sciences Corp antígenos derivados de 14-3-3 xitrulinada e usos dos mesmos no diagnóstico de artrite reumatoide
AU2012328921B2 (en) 2011-10-24 2017-05-11 Abbvie Inc. Immunobinders directed against TNF
EP2771360A1 (en) 2011-10-24 2014-09-03 AbbVie Inc. Immunobinders directed against sclerostin
EP3603671A3 (en) 2011-10-28 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell-specific molecule
RU2681885C2 (ru) 2011-10-31 2019-03-13 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула с регулируемой конъюгацией между тяжелой цепью и легкой цепью
CA2856149A1 (en) 2011-11-08 2013-05-16 Pfizer Inc. Methods of treating inflammatory disorders using anti-m-csf antibodies
PE20141937A1 (es) 2011-11-16 2014-12-18 Amgen Inc Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico
CN104080909A (zh) 2011-11-30 2014-10-01 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
CN104220460A (zh) 2011-12-08 2014-12-17 安姆根有限公司 激动人lcat抗原结合蛋白和它们在疗法中的用途
EP2602621A1 (en) 2011-12-08 2013-06-12 Julius-Maximilians-Universität Würzburg LASP-1, a novel urinary marker for transitional cell carcinoma detection
CA2855840C (en) 2011-12-14 2023-08-29 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
MX356933B (es) 2011-12-14 2018-06-20 Abbvie Deutschland Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
WO2013096516A1 (en) 2011-12-19 2013-06-27 Xoma Technology Ltd. Methods for treating acne
US20150030602A1 (en) 2011-12-23 2015-01-29 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
SI2797952T1 (sl) 2011-12-28 2019-07-31 Immunoqure Ag Postopek za pripravo monoklonskih avto-protiteles z želeno specifičnostjo
MX2014008101A (es) 2011-12-30 2014-09-25 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17.
NZ714482A (en) 2012-01-27 2017-08-25 Abbvie Inc Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
EP2812443B1 (en) 2012-02-06 2019-05-29 Inhibrx, Inc. Cd47 antibodies and methods of use thereof
SG10201704849PA (en) 2012-02-09 2017-07-28 Chugai Pharmaceutical Co Ltd Modified fc region of antibody
CA2864702A1 (en) 2012-02-22 2013-08-29 Amgen Inc. Autologous mammalian models derived from induced pluripotent stem cells and related methods
ES2795419T3 (es) 2012-02-24 2020-11-23 Chugai Pharmaceutical Co Ltd Molécula de unión al antígeno que promueve la desaparición del antígeno vía Fc RIIB
NZ712508A (en) 2012-03-16 2018-06-29 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
RS57414B1 (sr) 2012-03-16 2018-09-28 Regeneron Pharma Antitela sa lakim lancem konstruisanim sa histidinom i genetički modifikovani glodari za generisanje istih
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
CA2865644A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US9751942B2 (en) 2012-03-29 2017-09-05 Chugai Seiyaku Kabushiki Kaisha Anti-LAMP5 antibody and utilization thereof
HUE037613T2 (hu) 2012-03-29 2018-09-28 Novimmune Sa Anti-TLR4 antitestek és azok felhasználása
CN103382223B (zh) 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
WO2013150623A1 (ja) 2012-04-04 2013-10-10 株式会社ペルセウスプロテオミクス 抗ｃｄｈ３（ｐ－カドヘリン）抗体の薬剤コンジュゲート
EP2836514A4 (en) 2012-04-13 2015-12-30 Childrens Medical Center TIKI INHIBITORS
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
SI2838918T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za proizvodnjo heterodimernih IG-podobnih molekul
SI3431492T1 (sl) 2012-04-27 2021-07-30 Novo Nordisk A/S Antigen-vezavni proteini liganda človeškega CD30
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
EP3511343A1 (en) 2012-05-04 2019-07-17 Dana Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
ES2856272T3 (es) 2012-05-30 2021-09-27 Chugai Pharmaceutical Co Ltd Molécula de unión a antígenos para eliminar antígenos agregados
JPWO2013180200A1 (ja) 2012-05-30 2016-01-21 中外製薬株式会社 標的組織特異的抗原結合分子
AR092325A1 (es) 2012-05-31 2015-04-15 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
CA2875783C (en) 2012-06-06 2018-12-11 Zoetis Llc Caninized anti-ngf antibodies and methods thereof
EP4310191A3 (en) 2012-06-14 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified fc region
US9127053B2 (en) 2012-06-22 2015-09-08 Cytomx Therapeutics, Inc. Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
WO2014007402A1 (ja) 2012-07-06 2014-01-09 京都府公立大学法人 眼細胞の分化マーカーおよび分化制御
AR091755A1 (es) 2012-07-12 2015-02-25 Abbvie Inc Proteinas de union a il-1
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
US10919953B2 (en) 2012-08-24 2021-02-16 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific Fc region variant
WO2014036562A2 (en) 2012-08-31 2014-03-06 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AU2013312529A1 (en) 2012-09-05 2015-04-16 The University Of Birmingham Target peptides for colorectal cancer therapy and diagnostics
US10393733B2 (en) 2012-09-19 2019-08-27 Dana-Farber Cancer Institute, Inc. Dynamic BH3 profiling
EP2711016A1 (en) 2012-09-21 2014-03-26 Covagen AG Novel IL-17A binding molecules and medical uses thereof
AU2013320972B2 (en) 2012-09-27 2018-08-30 Chugai Seiyaku Kabushiki Kaisha FGFR3 fusion gene and pharmaceutical drug targeting same
TWI609083B (zh) 2012-09-28 2017-12-21 Chugai Pharmaceutical Co Ltd Blood coagulation reaction assessment method
MX370848B (es) 2012-10-04 2020-01-08 Dana Farber Cancer Inst Inc Anticuerpos monoclonales humanos anti-pd-l1 y métodos de uso.
TW201811825A (zh) 2012-11-01 2018-04-01 美商艾伯維有限公司 抗-ｖｅｇｆ／ｄｌｌ４雙重可變區域免疫球蛋白及其用途
JP6212497B2 (ja) 2012-11-08 2017-10-11 国立大学法人 宮崎大学 トランスフェリン受容体を特異的に認識できる抗体
ES2784631T3 (es) 2012-12-03 2020-09-29 Novimmune Sa Anticuerpos anti-CD47 y métodos de uso de los mismos
WO2014093855A1 (en) 2012-12-13 2014-06-19 University Of Virginia Patent Foundation Target peptides for ovarian cancer therapy and diagnostics
LT2935326T (lt) 2012-12-21 2020-12-10 Biogen Ma Inc. Žmogaus antikūnai prieš tau baltymą
EP2940135B9 (en) 2012-12-27 2021-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
CA2896824A1 (en) 2012-12-31 2014-07-03 Neurimmune Holding Ag Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
EP2948478B1 (en) 2013-01-25 2019-04-03 Amgen Inc. Antibodies targeting cdh19 for melanoma
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
SG11201506132PA (en) 2013-02-06 2015-09-29 Inhibrx Llc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
MX362075B (es) 2013-03-14 2019-01-07 Abbott Lab Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
CA2906407A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
EP2970451A1 (en) 2013-03-14 2016-01-20 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment
WO2014159242A1 (en) 2013-03-14 2014-10-02 Novartis Ag Notch 3 mutants and uses thereof
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
CN105452292A (zh) 2013-03-14 2016-03-30 帕卡什·吉尔 使用结合细胞表面grp78的抗体进行癌症治疗
JP6739329B2 (ja) 2013-03-14 2020-08-12 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ Ｈｃｖコア脂質結合ドメインモノクローナル抗体
US9505849B2 (en) 2013-03-15 2016-11-29 Amgen Research (Munich) Gmbh Antibody constructs for influenza M2 and CD3
CN105142668B (zh) 2013-03-15 2018-04-27 达纳-法伯癌症研究院公司 治疗性肽
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
TW201512219A (zh) 2013-03-15 2015-04-01 Abbvie Inc 針對ＩＬ－１β及／或ＩＬ－１７之雙特異性結合蛋白
AU2014233198B2 (en) 2013-03-15 2019-06-27 Sutter West Bay Hospitals Falz for use as a target for therapies to treat cancer
TW201525001A (zh) 2013-03-15 2015-07-01 Amgen Res Munich Gmbh 包含ｎ－端ａｂｐ之單鏈結合分子
JP6427552B2 (ja) 2013-03-15 2018-11-21 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド フラビウイルス中和抗体およびその使用方法
WO2014144632A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Human pac1 antibodies
US9850297B2 (en) 2013-03-15 2017-12-26 Amgen Inc. Secreted frizzle-related protein 5 (SFRP5) binding proteins
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
CN113621057A (zh) 2013-04-02 2021-11-09 中外制药株式会社 Fc区变体
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
CN104140974B (zh) 2013-05-08 2017-09-29 科济生物医药（上海）有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
JP6537143B2 (ja) 2013-05-16 2019-07-03 国立大学法人京都大学 癌の予後を診断する方法
EP3003372B1 (en) 2013-06-07 2019-10-09 Duke University Inhibitors of complement factor h
JP6442404B2 (ja) 2013-06-11 2018-12-19 国立研究開発法人国立精神・神経医療研究センター 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
AU2014299916A1 (en) 2013-06-24 2015-12-24 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent comprising humanized anti-Epiregulin antibody as active ingredient for non-small-cell lung carcinoma excluding adenocarcinoma
CA2916259C (en) 2013-06-28 2024-02-20 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
WO2015001013A2 (en) 2013-07-03 2015-01-08 Immunoqure Ag Human anti-ifn-alpha antibodies
EP2820947A1 (en) 2013-07-05 2015-01-07 B Cell Design Transgenic non-human mammal for producing chimeric human immunoglobulin E antibodies
EP3033356B1 (en) 2013-08-14 2020-01-15 Sachdev Sidhu Antibodies against frizzled proteins and methods of use thereof
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
EP3047276B1 (en) 2013-09-19 2023-06-14 Dana-Farber Cancer Institute, Inc. Methods of bh3 profiling
WO2015041310A1 (ja) 2013-09-20 2015-03-26 中外製薬株式会社 抗プロテインｃ抗体による出血性疾患の治療
EP3050896B1 (en) 2013-09-27 2021-07-07 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
SG10201802295XA (en) 2013-10-01 2018-04-27 Kymab Ltd Animal Models and Therapeutic Molecules
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
CN113307873A (zh) 2013-11-11 2021-08-27 中外制药株式会社 含有改变了抗体可变区的抗原结合分子
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
AU2014358191B2 (en) 2013-12-04 2020-12-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
KR20160090904A (ko) 2013-12-06 2016-08-01 다나-파버 캔서 인스티튜트 인크. 치료 펩티드
TW201609093A (zh) 2013-12-27 2016-03-16 Chugai Pharmaceutical Co Ltd Ｆｇｆｒ門控蛋白變異基因及以其爲標的之醫藥
JP6722455B2 (ja) 2013-12-27 2020-07-15 中外製薬株式会社 等電点の低い抗体の精製方法
CN103865920B (zh) * 2013-12-31 2016-06-01 广州达恩基因科技有限公司 胚胎干细胞特有小分子多肽es61编码基因的克隆方法
TW201532513A (zh) * 2014-01-10 2015-09-01 Alfur Fu-Hsin Hung 能產生比小鼠ＩgＥ量高出許多的人源化ＩgＥ之基因轉殖動物
CN104774264B (zh) 2014-01-15 2018-09-14 上海易乐生物技术有限公司 抗人proBDNF单克隆抗体及其在疼痛中的作用
EP3105252B1 (en) 2014-02-12 2019-07-24 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
CA2939006A1 (en) 2014-03-14 2015-09-17 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers
US20170174751A1 (en) 2014-03-19 2017-06-22 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
WO2015143414A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
CA2943405A1 (en) 2014-03-31 2015-10-08 Debiopharm International Sa Fgfr fusions
CA2940585C (en) 2014-04-15 2023-08-08 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Differential diagnosis of eczema and psoriasis
EP4112070A1 (en) 2014-04-25 2023-01-04 Dana Farber Cancer Institute, Inc. Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
EP3137910B1 (en) 2014-04-30 2019-09-25 Klinikum rechts der Isar der Technischen Universität München Diagnosis of multiple sclerosis
CA2949237C (en) 2014-05-16 2022-08-23 Amgen Inc. Assay for detecting th1 and th2 cell populations
US20170198054A1 (en) 2014-05-21 2017-07-13 Dana-Farber Cancer Institute Methods for treating cancer with anti bip or anti mica antibodies
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
TWI831106B (zh) 2014-06-20 2024-02-01 日商中外製藥股份有限公司 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
CN112979828A (zh) 2014-07-17 2021-06-18 恺兴生命科技(上海)有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
WO2016016278A2 (en) 2014-07-29 2016-02-04 Neurimmune Holding Ag Human-derived anti-huntingtin (htt) antibodies and uses thereof
CA2952540C (en) 2014-07-31 2022-06-21 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res (Munich) Gmbh Constructos de anticuerpos para cdh19 y cd3
JP6749312B2 (ja) 2014-07-31 2020-09-02 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ 最適化された種間特異的二重特異性単鎖抗体コンストラクト
WO2016027859A1 (ja) 2014-08-20 2016-02-25 中外製薬株式会社 蛋白質溶液の粘度測定方法
WO2016040767A2 (en) 2014-09-12 2016-03-17 Amgen Inc. Chrdl-1 epitopes and antibodies
MX2017003247A (es) 2014-09-15 2017-11-30 Amgen Inc Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
WO2016044588A1 (en) 2014-09-19 2016-03-24 The Regents Of The University Of Michigan Staphylococcus aureus materials and methods
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
SG11201701925XA (en) 2014-09-30 2017-04-27 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (dprs) antibody
EP3201232A1 (en) 2014-10-03 2017-08-09 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
JP6795505B2 (ja) 2014-10-06 2020-12-02 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法
MX2017004769A (es) 2014-10-15 2017-10-16 Amgen Inc Elementos promotores y reguladores para mejorar la expresion de genes heterologos en celulas hospederas.
CA2967379A1 (en) 2014-11-18 2016-05-26 Janssen Pharmaceutica Nv Cd47 antibodies, methods, and uses
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
EP3034620A1 (en) 2014-12-17 2016-06-22 Diaxonhit Compositions and methods for diagnosing thyroid cancer
FR3030758A1 (fr) 2014-12-19 2016-06-24 Inst Nat De La Rech Agronomique (Inra) Marqueurs diagnostiques de la maladie de crohn
US9969800B2 (en) 2015-02-05 2018-05-15 Chugai Seiyaku Kabushiki Kaisha IL-8 antibodies
CA2972393A1 (en) 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
EP3265491A1 (en) 2015-03-03 2018-01-10 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
CN107223135B (zh) 2015-03-16 2021-11-02 亥姆霍兹慕尼黑中心-德国环境健康研究中心(Gmbh) 用于治疗hbv感染和相关病症的三特异性结合分子
AU2016232749B2 (en) 2015-03-18 2021-09-23 The Johns Hopkins University Novel monoclonal antibody inhibitors targeting potassium channel KCNK9
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
CN116327915A (zh) 2015-04-03 2023-06-27 佐马技术有限公司 使用TGF-β抑制剂和PD-1抑制剂治疗癌症
WO2016164835A1 (en) 2015-04-08 2016-10-13 Dana-Farber Cancer Institute, Inc. Humanized influenza monoclonal antibodies and methods of use thereof
KR102057767B1 (ko) 2015-04-17 2019-12-19 에프. 호프만-라 로슈 아게 응고 인자 및 다중특이적 항체의 조합 요법
KR20180023892A (ko) 2015-04-17 2018-03-07 암젠 리서치 (뮌헨) 게엠베하 Cdh3 및 cd3에 대한 이중 특이성 항체 작제물
MX2017013383A (es) 2015-04-20 2017-12-07 Tolero Pharmaceuticals Inc Prediccion de respuesta a alvocidib mediante perfilado mitocondrial.
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
CA2983022C (en) 2015-04-27 2023-03-07 Dana-Farber Cancer Institute, Inc. High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells
RS59847B1 (sr) 2015-04-28 2020-02-28 Mitsubishi Tanabe Pharma Corp Protein koji vezuje rgma i njegova upotreba
AU2016258742B9 (en) 2015-05-01 2023-07-13 Dana-Farber Cancer Institute, Inc. Methods of mediating cytokine expression with anti CCR4 antibodies
TR201911032T4 (tr) 2015-05-18 2019-08-21 Tolero Pharmaceuticals Inc Artırılmış biyoyararlanıma sahip alvocıdıb ön ilaçları.
FR3036287A1 (fr) 2015-05-19 2016-11-25 Univ Bordeaux Traitement et detection des trypanosomes
SI3303395T1 (sl) 2015-05-29 2020-03-31 Abbvie Inc. Protitelesa proti CD40 in njihove uporabe
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
AU2016301315C1 (en) 2015-08-03 2022-07-07 Sumitomo Pharma Oncology, Inc. Combination therapies for treatment of cancer
US10253101B2 (en) 2015-08-06 2019-04-09 Xoma (Us) Llc Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
MA45352A (fr) 2015-08-07 2018-06-13 Univ Birmingham Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
WO2017049004A1 (en) 2015-09-15 2017-03-23 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
TWI814162B (zh) 2015-09-18 2023-09-01 日商中外製藥股份有限公司 Il-8結合抗體及其用途
JP2018529729A (ja) 2015-10-01 2018-10-11 アムジエン・インコーポレーテツド 胆汁酸障害の処置
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
JP6975720B2 (ja) 2015-11-30 2021-12-01 シェ、ヤンホイXie Yanhui 腫瘍の診断および治療におけるＡｋｔ２の使用
WO2017106578A1 (en) 2015-12-15 2017-06-22 Amgen Inc. Pacap antibodies and uses thereof
WO2017112824A2 (en) 2015-12-23 2017-06-29 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
WO2017110980A1 (ja) 2015-12-25 2017-06-29 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
US10781264B2 (en) 2016-02-03 2020-09-22 Amgen Research (Munich) Gmbh PSMA and CD3 bispecific T cell engaging antibody constructs
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
CR20180420A (es) 2016-02-03 2018-12-05 Amgen Inc Constructos de anticuerpo biespecíficos para bcma y cd3 que se ligan a células t
WO2017136676A1 (en) 2016-02-05 2017-08-10 Nanoview Diagnostics Inc. Detection of exosomes having surface markers
KR20180116215A (ko) 2016-03-14 2018-10-24 추가이 세이야쿠 가부시키가이샤 암의 치료에 이용하기 위한 세포상해 유도 치료제
EP3430058A4 (en) 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
JP7137474B2 (ja) 2016-03-15 2022-09-14 メルサナ セラピューティクス，インコーポレイティド ＮａＰｉ２ｂ標的化抗体－薬物コンジュゲート及びその使用方法
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
JP7082967B2 (ja) 2016-07-22 2022-06-09 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド グルココルチコイド誘導性腫瘍壊死因子受容体（ｇｉｔｒ）抗体及びその使用方法
EP3487867A2 (en) 2016-07-22 2019-05-29 Amgen Inc. Methods of purifying fc-containing proteins
JP7148493B2 (ja) 2016-08-01 2022-10-05 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー 副甲状腺ホルモン受容体１（ｐｔｈ１ｒ）抗体およびその使用
CA3035081A1 (en) 2016-09-02 2018-03-08 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
EP3509633A1 (en) 2016-09-06 2019-07-17 Dana-Farber Cancer Institute, Inc. Methods of treating or preventing zika virus infection
MX2019002510A (es) 2016-09-06 2019-06-24 Chugai Pharmaceutical Co Ltd Metodos para usar un anticuerpo biespecifico que reconoce el factor de coagulacion ix y/o el factor de coagulacion ix activado y el factor de coagulacion x y/o factor de coagulacion x activado.
WO2018049261A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
JP2019534710A (ja) 2016-09-28 2019-12-05 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー インターロイキン２に結合する抗体およびその使用
MX2019003473A (es) 2016-10-03 2019-10-15 Abbott Lab Metodos mejorados para evaluar el estado de ubiquitin carboxi-terminal hidrolasa l1 (uch-l1) en muestras de pacientes.
EP3535299A1 (en) 2016-11-04 2019-09-11 Novimmune S.A. Anti-cd19 antibodies and methods of use thereof
EP3538555A1 (en) 2016-11-14 2019-09-18 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
BR112019008265A2 (pt) 2016-11-28 2019-07-09 Chugai Pharmaceutical Co Ltd molécula de ligação ao ligante cuja atividade de li-gação ao ligante é ajustável
KR20190099260A (ko) 2016-12-19 2019-08-26 톨레로 파마수티컬스, 인크. 프로파일링 펩티드 및 감도 프로파일링을 위한 방법
WO2018129284A1 (en) 2017-01-05 2018-07-12 The Johns Hopkins University Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (psma)
MX2019008029A (es) 2017-01-06 2019-12-11 Abl Bio Inc Anticuerpo anti-alfa-sinucleina y su uso.
WO2018128454A1 (ko) 2017-01-06 2018-07-12 에이비엘바이오 주식회사 항 α-SYN 항체 및 그 용도
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
EP3570668A1 (en) 2017-01-19 2019-11-27 Open Monoclonal Technology, Inc. Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
WO2018175942A1 (en) 2017-03-23 2018-09-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
KR20190133005A (ko) 2017-03-24 2019-11-29 젠야쿠코교가부시키가이샤 항 IgM/B 세포 표면 항원 이중 특이성 항체
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
US10722589B2 (en) 2017-04-03 2020-07-28 Covagen Ag FGFR3 binding molecules
JOP20190243A1 (ar) 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
CA3053409A1 (en) 2017-04-15 2018-10-18 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2018199214A1 (ja) 2017-04-27 2018-11-01 中外製薬株式会社 薬物動態が改善された血液凝固第ｉｘ因子
BR112019022476A2 (pt) 2017-04-28 2020-05-12 Abbott Laboratories Métodos para o auxílio no diagnóstico e determinação hiperagudos de lesão cerebral traumática usando biomarcadores iniciais em pelo menos duas amostras a partir do mesmo ser humano
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
US11918650B2 (en) 2017-05-05 2024-03-05 Amgen Inc. Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
US10866251B2 (en) 2017-05-25 2020-12-15 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
WO2018215835A1 (en) 2017-05-26 2018-11-29 Novimmune Sa Anti-cd47 x anti-mesothelin antibodies and methods of use thereof
BR112019025387A2 (pt) 2017-05-30 2020-07-07 Abbott Laboratories métodos para auxiliar no diagnóstico e avaliação de uma lesão traumática cerebral branda em um indivíduo humano com o uso de troponina cardíaca i e biomarcadores precoces
JOP20190259A1 (ar) 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
CN110831969B (zh) 2017-06-20 2024-06-21 安进公司 使用抑胃肽受体（gipr）结合蛋白与glp-1激动剂的组合治疗或改善代谢障碍的方法
CR20200076A (es) 2017-07-14 2020-06-10 Pfizer ANTICUERPOS CONTRA MAdCAM
JP7504025B2 (ja) 2017-08-04 2024-06-21 アムジエン・インコーポレーテツド Ｃｙｓ－ｍａｂのコンジュゲーション方法
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
JP7266532B2 (ja) 2017-11-28 2023-04-28 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
KR20200106495A (ko) 2017-11-29 2020-09-14 보오드 오브 리젠츠, 더 유니버시티 오브 텍사스 시스템 암 치료요법을 위한 조성물 및 방법
US11022617B2 (en) 2017-12-09 2021-06-01 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1)
CN110892266A (zh) 2017-12-09 2020-03-17 雅培实验室 使用gfap和uch-l1的组合辅助诊断和评价人类受试者中创伤性脑损伤的方法
SG11202004273YA (en) 2017-12-11 2020-06-29 Amgen Inc Continuous manufacturing process for bispecific antibody products
WO2019117684A1 (ko) 2017-12-14 2019-06-20 에이비엘바이오 주식회사 a-syn/IGF1R에 대한 이중 특이 항체 및 그 용도
TWI817974B (zh) 2017-12-28 2023-10-11 日商中外製藥股份有限公司 細胞毒性誘導治療劑
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
AU2019207812A1 (en) 2018-01-12 2020-07-23 Bristol-Myers Squibb Company Combination therapy with anti-IL-8 antibodies and anti-PD-1 antibodies for treating cancer
CA3087951A1 (en) 2018-01-12 2019-07-18 Amgen Inc. Pac1 antibodies and uses thereof
JP7458790B2 (ja) 2018-01-31 2024-04-01 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
RU2020129265A (ru) 2018-03-12 2022-04-12 ЗОИТИС СЕРВИСЕЗ ЭлЭлСи Антитела против ngf и связанные с ними способы
AU2019235523A1 (en) 2018-03-14 2020-10-29 Novimmune Sa Anti-CD3 epsilon antibodies and methods of use thereof
US20210196568A1 (en) 2018-05-21 2021-07-01 Chugai Seiyaku Kabushiki Kaisha Lyophilized formulation sealed in glass container
WO2019225787A1 (ko) 2018-05-24 2019-11-28 에이비엘바이오 주식회사 항-b7-h3 항체 및 그 용도
CN108707599A (zh) * 2018-05-31 2018-10-26 东北农业大学 一种小鼠胚胎干细胞单细胞融合方法
US20210364412A1 (en) 2018-06-01 2021-11-25 NanoView Biosciences, Inc. Compositions, systems, and methods for enhanced label-free and fluorescence - based detection of nanoparticles
WO2020013238A1 (ja) 2018-07-10 2020-01-16 田辺三菱製薬株式会社 末梢神経障害又は末梢神経障害若しくはアストロサイト障害が認められる疾患に伴う疼痛の予防又は治療方法
US20210301017A1 (en) 2018-07-30 2021-09-30 Amgen Research (Munich) Gmbh Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
CA3107192A1 (en) 2018-08-03 2020-02-06 Amgen Research (Munich) Gmbh Antibody constructs for cldn18.2 and cd3
JP2021534779A (ja) 2018-08-27 2021-12-16 アフィメッド ゲゼルシャフト ミット ベシュレンクテル ハフツンク 抗体構築物がプレロードされた凍結保存ｎｋ細胞
SG11202103275YA (en) 2018-10-11 2021-04-29 Amgen Inc Downstream processing of bispecific antibody constructs
WO2020117988A1 (en) 2018-12-04 2020-06-11 Tolero Pharmaceuticals, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
JPWO2020153467A1 (ja) 2019-01-24 2021-12-02 中外製薬株式会社 新規がん抗原及びそれらの抗原に対する抗体
US20220125754A1 (en) 2019-01-29 2022-04-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Treating the causative agent in adhesiogenesis
WO2020160402A1 (en) 2019-02-01 2020-08-06 NanoView Biosciences, Inc. Systems and methods for vesicle cargo labeling and detection
EP3912992A4 (en) 2019-02-04 2022-11-23 National University Corporation Ehime University CAR LIBRARY AND MANUFACTURING PROCESSES FOR SCFV
WO2020167912A1 (en) 2019-02-13 2020-08-20 The Brigham And Women's Hospital, Inc. Anti-peripheral lymph node addressin antibodies and uses thereof
CN113508140A (zh) 2019-02-28 2021-10-15 学校法人顺天堂 与切断型的突变型Calreticulin结合的抗体以及骨髄增殖性肿瘤的诊断、预防或治疗药
EP3943108A4 (en) 2019-03-19 2023-01-04 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE CONTAINING AN ANTIGEN-BINDING DOMAIN WHOSE ANTIGEN-BINDING ACTIVITY IS ALTERED DEPENDING ON THE MTA, AND BANK FOR OBTAINING SUCH ANTIGEN-BINDING DOMAIN
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
SG11202110986YA (en) 2019-04-10 2021-11-29 Chugai Pharmaceutical Co Ltd Method for purifying fc region-modified antibody
KR20220019670A (ko) 2019-04-17 2022-02-17 고쿠리츠다이가쿠호진 히로시마다이가쿠 Il-6 저해제 및 ccr2 저해제를 조합하여 투여하는 것을 특징으로 하는 비뇨기암의 치료제
CN114174344A (zh) 2019-05-30 2022-03-11 美国安进公司 工程改造铰链区以驱动抗体二聚化
BR112021023735A2 (pt) 2019-06-05 2022-01-04 Chugai Pharmaceutical Co Ltd Molécula de ligação de sítio de clivagem de anti-corpo
MX2021014644A (es) 2019-06-13 2022-04-06 Amgen Inc Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos.
MX2021015791A (es) 2019-06-28 2022-04-01 Amgen Inc Proteínas de unión al antígeno biespecificas anti-receptor de cgrp/anti-receptor pac1.
WO2021021676A1 (en) 2019-07-26 2021-02-04 Amgen Inc. Anti-il13 antigen binding proteins
MX2022002981A (es) 2019-09-10 2022-04-06 Amgen Inc Metodo de purificacion para polipeptidos de union a antigeno biespecificos con capacidad de union dinamica de captura de proteina l mejorada.
CN115175680A (zh) 2019-10-18 2022-10-11 加利福尼亚大学董事会 Plxdc激活剂及其用于治疗血管病症的用途
US20220389119A1 (en) 2019-11-08 2022-12-08 Amgen Inc. ENGINEERING CHARGE PAIR MUTATIONS FOR PAIRING OF HETERO-IgG MOLECULES
WO2021097344A1 (en) 2019-11-13 2021-05-20 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
JP2023501717A (ja) 2019-11-19 2023-01-18 アムジエン・インコーポレーテツド 新規の多重特異性抗体フォーマット
CA3164129A1 (en) 2019-12-20 2021-06-24 Amgen Inc. Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors
AR120898A1 (es) 2019-12-26 2022-03-30 Univ Osaka Agente para tratar o prevenir neuromielitis óptica en fase aguda
WO2021130383A1 (en) 2019-12-27 2021-07-01 Affimed Gmbh Method for the production of bispecific fcyriii x cd30 antibody construct
WO2021145432A1 (ja) 2020-01-15 2021-07-22 国立大学法人大阪大学 糖尿病性自律神経障害の予防又は治療剤
AU2021207010A1 (en) 2020-01-15 2022-08-25 Mitsubishi Tanabe Pharma Corporation Prophylactic or therapeutic agent for dementia
WO2021150824A1 (en) 2020-01-22 2021-07-29 Amgen Research (Munich) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
US11896619B2 (en) 2020-03-10 2024-02-13 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer
US20230146593A1 (en) 2020-03-12 2023-05-11 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecific antibodies binding to cds x cancer cell and tnf alpha or il-6 inhibitor
CN115427454A (zh) 2020-03-19 2022-12-02 安进公司 针对粘蛋白17的抗体及其用途
JP7329288B2 (ja) 2020-03-27 2023-08-18 株式会社PhotoQ3 腫瘍細胞を死滅させるための医薬
JPWO2021206078A1 (no) 2020-04-06 2021-10-14
CA3175523A1 (en) 2020-04-13 2021-10-21 Antti Virtanen Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
AU2021275049A1 (en) 2020-05-19 2022-12-22 Amgen Inc. MAGEB2 binding constructs
CN115667515A (zh) 2020-05-22 2023-01-31 中外制药株式会社 中和具有凝血因子viii(f.viii)功能替代活性的物质的抗体
WO2021243320A2 (en) 2020-05-29 2021-12-02 Amgen Inc. Adverse effects-mitigating administration of a bispecific antibody construct binding to cd33 and cd3
CN115803062A (zh) 2020-06-03 2023-03-14 博泰康医药公司 滋养层细胞表面抗原2(trop-2)抗体
KR20230026407A (ko) 2020-06-18 2023-02-24 리제너론 파아마슈티컬스, 인크. 액티빈 a 항체 제형 및 이의 사용 방법
EP4174071A4 (en) 2020-06-24 2024-09-11 Univ Tokyo PHOTOSENSITIZING DYE
WO2022006562A1 (en) 2020-07-03 2022-01-06 Dana-Farber Cancer Institute, Inc. Multispecific coronavirus antibodies
JP2023534987A (ja) 2020-07-24 2023-08-15 アムジエン・インコーポレーテツド Ｓａｒｓ－ｃｏｖ２スパイクタンパク質に由来する免疫原
KR20230047397A (ko) 2020-07-28 2023-04-07 추가이 세이야쿠 가부시키가이샤 신규 개변형 항체를 포함하는, 바늘 실드를 구비한 바늘 부가 프리필드 시린지 제제
MX2023001120A (es) 2020-07-31 2023-02-22 Chugai Pharmaceutical Co Ltd Composicion farmaceutica que comprende una celula que expresa un receptor quimerico.
WO2022031804A1 (en) 2020-08-04 2022-02-10 Abbott Laboratories Improved methods and kits for detecting sars-cov-2 protein in a sample
WO2022040466A1 (en) 2020-08-20 2022-02-24 Amgen Inc. Antigen binding proteins with non-canonical disulfide in fab region
AU2021331170A1 (en) 2020-08-27 2023-03-23 Juntendo Educational Foundation Anti-cleaved mutant calr-cd3 bispecific antibody and pharmaceutical composition
AU2021358033A1 (en) 2020-10-07 2023-05-04 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
AU2021357841A1 (en) 2020-10-08 2023-06-15 Affimed Gmbh Trispecific binders
US12006550B2 (en) 2020-10-12 2024-06-11 University Of South Carolina Targeting treatment for ADAM30 in pathological cells
TW202225188A (zh) 2020-11-06 2022-07-01 德商安美基研究（慕尼黑）公司 與ｃｄ３結合的多肽構建體
KR20230098334A (ko) 2020-11-06 2023-07-03 암젠 리서치 (뮌헨) 게엠베하 Cldn6 및 cd3에 선택적으로 결합하는 폴리펩디드 작제물
UY39508A (es) 2020-11-06 2022-05-31 Amgen Res Munich Gmbh Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada
IL301926A (en) 2020-11-06 2023-06-01 Amgen Inc Antigen binding domain with reduced cleavage rate
MX2023005379A (es) 2020-11-10 2023-05-23 Amgen Inc Enlazadores novedosos de dominios de union a antigenos multiespecificos.
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2022119841A1 (en) 2020-12-01 2022-06-09 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2022147147A1 (en) 2020-12-30 2022-07-07 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
KR20230156368A (ko) 2021-03-12 2023-11-14 추가이 세이야쿠 가부시키가이샤 중증 근무력증의 치료 또는 예방용의 의약 조성물
CA3212599A1 (en) 2021-03-22 2022-09-29 Novimmune S.A. Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
US20220315655A1 (en) 2021-03-22 2022-10-06 Novimmune Sa Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
MX2023011690A (es) 2021-04-02 2023-12-15 Amgen Inc Construcciones de unión a mageb2.
WO2022225921A1 (en) 2021-04-20 2022-10-27 Amgen Inc. Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly
WO2022232376A1 (en) 2021-04-29 2022-11-03 Amgen Inc. Methods for reducing low molecular weight species of recombinantly-produced proteins
EP4334358A1 (en) 2021-05-06 2024-03-13 Amgen Research (Munich) GmbH Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
US20240262917A1 (en) 2021-05-06 2024-08-08 Dana-Farber Cancer Institute, Inc. Antibodies against alk and methods of use thereof
EP4341699A1 (en) 2021-05-18 2024-03-27 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
US20240118279A1 (en) 2021-06-14 2024-04-11 Abbott Laboratories Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
IL308154A (en) 2021-07-30 2023-12-01 Affimed Gmbh Double structure antibodies
CA3230038A1 (en) 2021-08-31 2023-03-09 Hongwei Zhang Methods and systems of diagnosing brain injury
EP4406556A1 (en) 2021-09-24 2024-07-31 PhotoQ3 Inc. Medicine for killing tumor cells
AU2022354059A1 (en) 2021-09-30 2024-03-28 Abbott Laboratories Methods and systems of diagnosing brain injury
WO2023057871A1 (en) 2021-10-04 2023-04-13 Novartis Ag Surfactant stabilizers
WO2023058705A1 (ja) 2021-10-08 2023-04-13 中外製薬株式会社 抗ｈｌａ－ｄｑ２．５抗体の製剤
KR20240099407A (ko) 2021-11-03 2024-06-28 아피메트 게엠베하 이중특이적 cd16a 결합제
MX2024005106A (es) 2021-11-03 2024-07-02 Affimed Gmbh Ligandos biespecificos de cd16a.
IL312538A (en) 2021-11-05 2024-07-01 Abviro Llc Broadly reactive human monoclonal influenza antibodies and methods for their use
AU2022396272A1 (en) 2021-11-24 2024-06-06 Dana-Farber Cancer Institute, Inc. Antibodies against ctla-4 and methods of use thereof
CA3239389A1 (en) 2021-12-01 2023-06-08 Kohei SOEDA Method for preparing antibody-containing formulation
CA3240822A1 (en) 2021-12-17 2023-06-22 Tony Lee Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
CA3241407A1 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Platform for antibody discovery
CA3241395A1 (en) 2021-12-17 2023-06-22 Barbel SCHROFELBAUER Antibodies and uses thereof
US20230213536A1 (en) 2021-12-28 2023-07-06 Abbott Laboratories Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
WO2023150652A1 (en) 2022-02-04 2023-08-10 Abbott Laboratories Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
WO2023178357A1 (en) 2022-03-18 2023-09-21 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules and methods of use thereof
WO2023218027A1 (en) 2022-05-12 2023-11-16 Amgen Research (Munich) Gmbh Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
WO2024039670A1 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof
TW202421650A (zh) 2022-09-14 2024-06-01 美商安進公司 雙特異性分子穩定組成物
WO2024059708A1 (en) 2022-09-15 2024-03-21 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
US20240254234A1 (en) 2022-10-21 2024-08-01 Novimmune Sa PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION
WO2024173607A2 (en) 2023-02-14 2024-08-22 Evolveimmune Therapeutics, Inc. Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69133566T2 (de) * 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
EP0814159B1 (en) * 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
GB9119338D0 (en) * 1991-09-10 1991-10-23 Inst Of Animal Physiology And Control of gene expression
JPH07508410A (ja) * 1992-06-18 1995-09-21 ジェンファーム　インターナショナル　インコーポレイテッド 酵母人工染色体を有するトランスジェニック非ヒト動物の製造方法

Also Published As

Publication number Publication date
ES2301158T3 (es) 2008-06-16
NO950244L (no) 1995-03-23
EP0652950A4 (en) 1997-05-07
JP2007125020A (ja) 2007-05-24
FI121339B (fi) 2010-10-15
FI950277A (fi) 1995-03-21
AU4781993A (en) 1994-02-14
ATE381614T1 (de) 2008-01-15
NZ255101A (en) 1997-08-22
JPH07509137A (ja) 1995-10-12
EP0652950A1 (en) 1995-05-17
SG48760A1 (en) 2003-03-18
CA2140638A1 (en) 1994-02-03
FI950277A0 (fi) 1995-01-23
EP0652950B1 (en) 2007-12-19
AU675661B2 (en) 1997-02-13
WO1994002602A1 (en) 1994-02-03
NO328075B1 (no) 2009-11-23
CA2140638C (en) 2010-05-04

Similar Documents

Publication Publication Date Title
NO950244D0 (no) Dannelse av xenogene antistoffer
DK0463151T3 (da) Frembringelse af xenogene antistoffer
EP0648265A4 (en) PROCESS FOR THE PRODUCTION OF NON-HUMAN TRANSGENIC ANIMALS HAVING AN ARTIFICIAL YEAST CHROMOSOME.
Zhou et al. Generation of CRISPR/Cas9-mediated gene-targeted pigs via somatic cell nuclear transfer
DK0843961T3 (da) Kimærisk mus og fremgangsmåde til at producere samme
ATE332077T1 (de) Transgene mäuse die ein menschliche antikörper exprimieren
TWI255853B (en) Method for modifying chromosomes
BR9506652A (pt) Materiais e métodos para gerenciamento de rejeição hiperaguda em xenotransplante em ser humano
NO911164D0 (no) Homolog rekombinasjon for universale donatorceller og chimere pattedyrverter.
WO2000011151A3 (en) Direct oviduct transgenesis
ATE217905T1 (de) Zellinien, die einen biologisch aktiven faktor-ix exprimieren
GB2369828A (en) Nuclear transfer with selected donor cells
SE9701345D0 (sv) Transgenic, non-human animal with protein deficiency, cells derived therefrom, use of said animal and cells, and method ofpr oducing said transgenic animal
CA2037907A1 (en) Homologous recombination for universal donor cells and chimeric mammalian hosts
MX9603037A (es) Materiales y metodos para manejar rechazo hiperagudo en xenotrasplante humano.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees